Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA accepts NDA for dual Srk and Abl inhibitor bosutinib in previously-treated Philadelphia chromosome-positive CML on a positive news day for Pfizer. Meanwhile, review in front-line CML is pending in Europe.

Advertisement

Related Content

Eisai Will Make “Totality Of The Evidence” Argument At FDA Panel Review Of Dacogen
Business News, In Brief
Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile
Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile
Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH
Tasigna Beats Sprycel To First-Line CML Punch

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel